Sequencing in the cGVHD Treatment Paradigm

Leyla O. Shune, MD, discusses sequencing agents in the in current treatment paradigm for chronic graft-versus-host disease, given the multitude of available FDA-approved agents and additional treatments emerging on the horizon. Shune sees opportunities for more personalized care as well as the potential to move novel treatments earlier in the sequencing pathway with the potential for steroid-sparing approaches.